Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $130 from $125 and keeps a Buy rating on the shares. The firm updated the company’s model post the Q1 report. It views Protagonist’s quarter as “transformative” with the Icotyde approval.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics price target raised to $137 from $120 at Citizens
- Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
- Protagonist Therapeutics management to meet virtually with Clear Street
- Protagonist Therapeutics participates in a conference call with JPMorgan
- Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide